Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 16Brain Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Endometrial Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Site 2Neoplasms 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Osteosarcoma 1Neurofibromatosis 1 1Neuroblastoma 1Multiple Myeloma 1Medulloblastoma 1Lung Neoplasms 1Liposarcoma 1

Interventions

pembrolizumab 2lenvatinib 1abemaciclib 1Tablets 1Docetaxel 1Combined Modality Therapy 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Adenoid Cystic × abemaciclib × Clear all
NCT05774899 2025-06-17

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
32 enrolled

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡